FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for SCEMBLIX (asciminib) submitted by Novartis, resulting in changes to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

SUPPL AP for SCEMBLIX (ASCIMINIB)